

## Bibliografia

1. Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. *Arch Intern Med.* 1995;155:469-574
2. Falk R. Atrial fibrillation. *N Engl J Med* 2001; 344: 1067-1078
3. Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. *Am J Cardiol.* 1998;82:2N-9N.
4. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults. *JAMA* 2001; 285: 2370-2375
5. Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. *Ann Intern Med.* 1999;131:492-501.
6. Sudlow M, Thomson R, Thwaites B, et al. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. *Lancet.* 1998;325:1167-1171.
7. McCrory DC, Matchar DB, Samsa G, et al. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. *Arch Intern Med.* 1995;155:277-281.
8. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study. *Stroke.* 1996;27:1760-1764.
9. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation. *Chest* 2004; 126: 429S-456S
10. Kannel WB. Blood pressure as a cardiovascular risk factor. *JAMA.* 1990;275:1571-1576.
11. White RH, McBurnie MA, Manolio T, et al. Oral anticoagulation in patients with atrial fibrillation: adherence with guidelines in an elderly cohort. *Am J Med.* 1999;106:165-171.
12. Wynne HA, Kamali F, Edwards C, et al. Effect of ageing upon warfarin dose requirements: a longitudinal study. *Age Ageing.* 1996;25:429-431.
13. Montamat SC, Cusack B. Overcoming problems with polypharmacy and drug misuse in the elderly. *Clin Geriatr Med.* 1992;8:143-158.
14. Monette J, Gurwitz JH, Rochon PA, et al. Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: results of a survey of long-term care practitioners. *J Am Geriatr Soc.* 1997;45:60-65.
15. Man-Son-Hing M, Nichol G, Lau A, et al. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. *Arch Intern Med.* 1999;159:677-685.
16. Hylek EM, Skates SJ, Sheehan MA, et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with non-rheumatic atrial fibrillation. *N Engl J Med.* 1996;335:540-546.
17. The Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. *Arch Intern Med.* 1996;156:409-416.
18. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. *Lancet.* 1996;348:633-638.
19. Palareti G, Hirsh J, Legnani C, et al. Oral anticoagulation treatment in the elderly: a nested prospective, case-control study. *Arch Intern Med.* 2000;160:470-478.

20. Atrial Fibrillation Investigators. Echocardiographic predictors of stroke in patients with atrial fibrillation. *Arch Intern Med.* 1998;158:1316-1320.
21. Hart RG. Intensity of anticoagulation to prevent stroke in patients with atrial fibrillation. *Ann Intern Med.* 1998;128:408.
22. Final consensus statement of the Royal College of Physicians of Edinburgh Consensus Conference on atrial fibrillation in hospital and general practice, 3-4 September 1998. *Br J Haematol.* 1999;104: 195-196.
23. Beyth RG, Quinn L, Landefeld CS, et al. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial. *Ann Intern Med* 2000; 133: 687-695
24. Upshaw CB Jr. Hemodynamic changes after cardioversion of chronic atrial fibrillation. *Arch Intern Med.* 1997;157:1070-1076.
25. Daoud EG, Weiss R, Bahu M, et al. Effect of an irregular ventricular rhythm on cardiac output. *Am J Cardiol.* 1996;78:1433-1436.
26. Shinbane JS, Wood MA, Jensen DN, et al. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. *J Am Coll Cardiol.* 1997;29:709-715.
27. Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. *Circulation.* 1990;82:1106-1116.
28. Reimold SC, Chalmers TC, Berlin JA, et al. Assessment of the efficacy and safety of antiarrhythmic therapy for chronic atrial fibrillation: observations on the role of trial design and implications of drug-related mortality. *Am Heart J.* 1992;124:924-932.
29. Flaker GC, Blackshear JL, McBride R, et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. *J Am Coll Cardiol.* 1992;20:527-532.
30. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation—pharmacological intervention in atrial fibrillation (PIAF): a randomised trial. *Lancet.* 2000;356:1789-1794.
31. Wyse DG, Waldo AL, DiMarco JP, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. *N Engl J Med.* 2002;347:1825-1833.
32. Van Gelder IC, Hagens VE, Bosker HA, et al. Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) Study Group. *N Engl J Med.* 2002;347:1834-1840.
33. Carlsson J, Miketic S, Windler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillations: (STAF) Strategies of Treatment of Atrial Fibrillation) study. *J Am Coll Cardiol.* 2003;41:1690-1696.
34. Opolski G, Torbicki A, Kosior DA, et al. Rate Control vs Rhythm Control in Patients With Nonvalvular Persistent Atrial Fibrillation. The Results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. *Chest* 2004; 126: 476-486
35. McNamara RL, Tamariz LJ, Segal JB, et al. Management of Atrial Fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. *Ann Intern Med.* 2003;139:1018-1033.
36. Gronefeld GC, Lilienthal J, Kuck KH, et al., for the Pharmacological Intervention in Atrial Fibrillation (PIAF) Study Group. Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Results from a prospective randomized trial. *Eur Heart J.* 2003;24:1430-1436.
37. Hagens VE, Ranchor AV, Van Sonderen E, et al., for the RACE Study Group. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from

- the Rate Control Versus Electrical Cardioversion (RACE) Study. *J Am Coll Cardiol.* 2004;43:241-247.
38. Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. *Circulation.* 2004;109:1509-1513
  39. The AF-CHF Investigators. Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trials. *Am Heart J.* 2002;144:597-607.
  40. Ross HM, Kokovic DZ, Kowey PR. Pharmacologic therapy for atrial fibrillation. *Am J Geriatr Cardiol* 2005; 14: 62-67
  41. Yadav A, Scheinman M. Atrial fibrillation in the elderly. *Am J geriatric cardiol* 2003; 12: 49-56
  42. Andersen HR, Nielsen JC, Thomsen PE, et al. Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick-sinus syndrome. *Lancet.* 1997;350:1210-1216.
  43. Connolly SJ, Kerr CR, Gent M, et al. Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. *N Engl J Med.* 2000;342:1385-1391.
  44. Lamas GA, Lee KL, Sweeney MO, et al. Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. *N Engl J Med.* 2002;346:1854-1862.
  45. Skanes AC, Krahn AD, Yee R, et al. Progression to chronic atrial fibrillation after pacing: the Canadian Trial of Physiologic Pacing. CTOPP Investigators. *J Am Coll Cardiol.* 2001;38:167-172.
  46. Bailin SJ, Adler S, Giudici M. Prevention of chronic atrial fibrillation by pacing in the region of Bachmann's bundle: results of a multicenter randomized trial. *J Cardiovasc Electrophysiol.* 2001;12:912-917.
  47. Padeletti L, Pieragnoli P, Ciapetti C, et al. Randomized crossover comparison of right atrial appendage pacing versus interatrial septum pacing for prevention of paroxysmal atrial fibrillation in patients with sinus bradycardia. *Am Heart J.* 2001;142:1047-1055.
  48. Gillis AM, Wyse DG, Connolly SJ, et al. Atrial pacing periablation for prevention of paroxysmal atrial fibrillation. *Circulation.* 1999;99:2553-2558.
  49. Padeletti L, Purerfellner H, Adler SW, et al. Combined efficacy of atrial septal lead placement and atrial pacing algorithms for prevention of paroxysmal atrial tachycardia. *J Cardiovasc Electrophysiol.* 2003;14:1189-1195.
  50. Lee MA, Weachter R, Pollak S, et al. The effect of atrial pacing therapies on atrial tachyarrhythmia burden and frequency: results of a randomized trial in patients with bradycardia and atrial tachyarrhythmias. *J Am Coll Cardiol.* 2003;41:1926-1932.
  51. Carlson MD, Ip J, Messenger J, et al. A new pacemaker algorithm for the treatment of atrial fibrillation: results of the Atrial Dynamic Overdrive Pacing Trial (ADOPT). *J Am Coll Cardiol.* 2003;42:627-633.
  52. Padeletti L, Santini M, Boriani G, et al. Temporal variability of atrial tachyarrhythmia burden in bradycardia-tachycardia syndrome patients. *Eur Heart J* 2005; 26: 165-172
  53. Cox JL, Schuessler RB, Lappas DG, et al. An 8 1/2-year clinical experience with surgery for atrial fibrillation. *Ann Surg.* 1996;224:267-275.
  54. Bando K, Kobayashi J, Kosakai Y, et al. Impact of Cox maze procedure on outcome in patients with atrial fibrillation and mitral valve disease. *J Thorac Cardiovasc Surg.* 2002;124:575-583.

55. Ernst S, Schluter M, Ouyang F, et al. Modification of the substrate for maintenance of idiopathic human atrial fibrillation: efficacy of radiofrequency ablation using nonfluoroscopic catheter guidance. *Circulation*. 1999;100:2085-2092.
56. Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. *N Engl J Med*. 1998;339:659-666.
57. Pappone C, Oreto G, Rosanio S, et al. Atrial electroanatomic remodeling after circumferential radiofrequency pulmonary vein ablation: efficacy of an anatomic approach in a large cohort of patients with atrial fibrillation. *Circulation*. 2001;104:2539-2544.
58. Cappato R, Calkins H, Chen SA, et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. *Circulation* 2005; 111: 1100-1105
59. Wood MA, Brown-Mahoney C, Kay GN, et al. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis. *Circulation*. 2000;101:1138-1144.
60. Brignole M, Gianfranchi L, Menozzi C, et al. Assessment of atrioventricular junction ablation and DDDR mode-switching pacemaker versus pharmacological treatment in patients with severely symptomatic paroxysmal atrial fibrillation: a randomized controlled study. *Circulation*. 1997;96:2617-2624.
61. Marshall HJ, Harris ZI, Griffith MJ, et al. Prospective randomized study of ablation and pacing versus medical therapy for paroxysmal atrial fibrillation: effects of pacing mode and mode-switch algorithm. *Circulation*. 1999;99:1587-1592.
62. Ozcan C, Jahangir A, Friedman PA, et al. Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. *N Engl J Med*. 2001;344:1043-1051.
63. Ozcan C, Jahangir A, Friedman PA, et al. Sudden death after radiofrequency ablation of the atrioventricular node in patients with atrial fibrillation. *J Am Coll Cardiol*. 2002;40:105-110.
64. Sweeney MO, Hellkamp AS, Ellenbogen KA, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. *Circulation*. 2003;107:2932-2937.